Boston, MA – April 1, 2023 – Claritas Genomics, a leading provider of genetic testing and interpretation services, announced today that it has changed its laboratory equipment to further improve the accuracy and reliability of its DNA sequencing. The company has invested in the state-of-the-art ILLUMINA HiSeq 2500 sequencing system, which will allow Claritas Genomics to offer even more precise and accurate genetic testing services to its customers.

In a statement, Claritas Genomics CEO Patrice Milos said, "We are thrilled to announce the addition of the ILLUMINA HiSeq 2500 sequencing system to our laboratory. This advanced technology will allow us to provide our customers with even more accurate and reliable genetic testing results, and it positions us well for continued growth and success in the years ahead."

Improved Sequencing Capabilities with ILLUMINA HiSeq 2500

The ILLUMINA HiSeq 2500 sequencing system is one of the most powerful and efficient sequencing technologies available. With its rapid run mode and high output mode, it provides quick results and allows efficient processing of a limited number of samples, as well as the ability to batch process larger studies. The rapid run mode, which supports longer paired-end 150 base pair reads, enables greater depth of coverage and improved assembly for de novo applications. The high output mode, on the other hand, allows you to batch process more than 6× more samples than rapid mode and to complete larger projects quickly and efficiently.

New HiSeq SBS Kits v4 produce 4 billion clusters per run, generating up to 1 terabyte (Tb) of data in just six days. The data generated by HiSeq SBS Kits v4 is high-quality and accurate, allowing researchers and clinicians to confidently identify genetic variations that may be present in a patient's DNA.

Improved Accuracy and Reliability

The ILLUMINA HiSeq 2500 sequencing system delivers unparalleled accuracy and reliability, which is crucial when it comes to genetic testing. With its superior base call accuracy and low error rates, the HiSeq 2500 system ensures that Claritas Genomics can confidently deliver reliable and accurate results to its customers.

Expertise and Quality Control

Claritas Genomics is staffed by a team of highly trained and experienced laboratory professionals, who use a rigorous quality control process to ensure that every sample is processed accurately and efficiently. The company's laboratory is CLIA-certified and adheres to all industry standards and regulations.

Building a Network of Top-Tier Pediatric Academic Centers

Claritas Genomics is committed to advancing genomic medicine and improving patient care. The company is currently developing relationships with other U.S. and international children's hospitals to create a network of top-tier pediatric academic centers that can share data, especially important for rare diseases that require large numbers of patients to discover genetic markers. By leveraging its expertise and resources, Claritas Genomics is well-positioned to make significant contributions to the field of genetic testing and to continue to drive innovation in genomics.

About Claritas Genomics

Claritas Genomics offers genetic testing and interpretation services to healthcare professionals, researchers, and patients. The company is majority-owned by Boston Children's Hospital and leverages expertise, assets, and personnel from the hospital's Genetic Diagnostic Lab. Claritas Genomics is committed to advancing genomic medicine and improving patient care through research, innovation, and high-quality service.

For more information, visit www.claritasgenomics.com.

Contact:

99 Erie Street Cambridge, MA 02139

clientservices@claritasgenomics.com

(617) 553 – 5880